# A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer

> **NCT00252811** · PHASE2 · WITHDRAWN · sponsor: **AstraZeneca** · enrollment: 60 (—)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Gefitinib

## Key facts

- **NCT ID:** NCT00252811
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2004-02
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 60 (—)
- **Last updated:** 2011-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00252811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00252811, "A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00252811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*